15 min listen
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition
ratings:
Length:
65 minutes
Released:
Dec 19, 2023
Format:
Podcast episode
Description
Dr David M O’Malley from The Ohio State University and the James Comprehensive Cancer Center in Columbus, Ohio discusses the role of HER2-directed therapy in the treatment of gynecologic cancers.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/1Gyn).
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/1Gyn).
Released:
Dec 19, 2023
Format:
Podcast episode
Titles in the series (100)
Dr Michael Pishvaian Comments on the Use of PARP Inhibition in the Management of Pancreatic Cancer: Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. by Oncology Today with Dr Neil Love